<DOC>
	<DOCNO>NCT00942747</DOCNO>
	<brief_summary>This open-label trial investigate efficacy temsirolimus recurrent refractory primary CNS lymphoma ( PCNSL ) initial chemotherapy high-dose methotrexate contain regimen . 37 patient plan treated weekly infusion 25mg Temsirolimus ( first 3 patient ) 75mg Temsirolimus ( patient ) maximum 12 month . The trial design two stage , le one first 12 patient responds treatment , trial stop . In addition efficacy , safety penetration temsirolimus cerebrospinal fluid investigate .</brief_summary>
	<brief_title>Temsirolimus Recurrent Primary Central Nervous System ( CNS ) Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Primary CNS lymphoma diagnose histologically cerebrospinal fluid cytology ; absence systemic lymphoma manifestation Relapse lymphoma progression after/during highdose methotrexate contain firstline chemotherapy alternative therapy case contraindication highdose methotrexate ECOG performance score ≤ 2 Age ≥18 year ≤ 75 year Life expectancy least 3 month Absence active infection Negative HIV serology Adequate renal function ( GFR &gt; 30ml/h ) Adequate bone marrow reserve ( neutrophils &gt; 1500/µl , platelet &gt; 80,000/µl ) Bilirubin &lt; 1.5x upper limit normal ( ULN ) , ALT AST &lt; 3x ULN At least 3 week interval prior cytostatic treatment Negative pregnancy test Patient accessible treatment followup Patient compliance Signed informed consent Secondary CNS lymphoma Primary intraocular lymphoma Patient eligible highdose chemotherapy autologous stemcell transplantation Concurrent treatment within another clinical trial Concurrent malignant disease Symptomatic congestive heart failure ( ≥NYHA II ) Active uncontrolled chronic infection Severe concomitant disease incompatible study conduct History cerebral bleeding Concomitant treatment strong CYP3A4/5inductors inhibitor Premenopausal woman without highly effective contraception ( define Pearl index &lt; 1 ) Pregnant lactate woman Refusal record pas pseudonymized disease treatment relate data part treatment protocol Concurrent admission psychiatric institution public order</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>temsirolimus , primary CNS lymphoma , PCNSL , salvage treatment</keyword>
</DOC>